New hope for kids with rare seizure disorder: drug trial launches

NCT ID NCT07600736

Recruiting now Disease control Sponsor: Actio Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests an experimental drug called ABS-1230 in children and young adults (ages 1 month to under 22 years) with a rare epilepsy caused by changes in the KCNT1 gene. The goal is to see if the drug is safe and can reduce the number of seizures compared to a placebo. Participants must have at least 4 seizures per week and cannot take certain other epilepsy medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABS-1230 (an experimental drug taken once daily)
What this could lead to: If it works, this could provide a new treatment option to reduce seizures in children with a rare, severe form of epilepsy.
What could go wrong: This is an early-phase trial with only 45 participants, so results may not apply to all. The drug may not reduce seizures or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates